Search Results - "Popa, Crina"

Modification of Bacterial Effector Proteins Inside Eukaryotic Host Cells by Popa, Crina M, Tabuchi, Mitsuaki, Valls, Marc

“…Pathogenic bacteria manipulate their hosts by delivering a number of virulence proteins -called effectors- directly into the plant or animal cells. Recent…”
Get full text

Efficient production and characterization of the novel and highly active antifungal protein AfpB from Penicillium digitatum by Garrigues, Sandra, Gandía, Mónica, Popa, Crina, Borics, Attila, Marx, Florentine, Coca, María, Marcos, Jose F., Manzanares, Paloma

“…Filamentous fungi encode distinct antifungal proteins (AFPs) that offer great potential to develop new antifungals. Fungi are considered immune to their own…”
Get full text

Biotechnological Production of the Cell Penetrating Antifungal PAF102 Peptide in Pichia pastoris by Popa, Crina, Shi, Xiaoqing, Ruiz, Tarik, Ferrer, Pau, Coca, María

“…Antimicrobial peptides (AMPs) have potent and durable antimicrobial activity to a wide range of fungi and bacteria. The growing problem of drug-resistant…”
Get full text

The awr Gene Family Encodes a Novel Class of Ralstonia solanacearum Type III Effectors Displaying Virulence and Avirulence Activities by SOLE, Montserrat, POPA, Crina, MITH, Oriane, KEE HOON SOHN, JONES, Jonathan D. G, DESLANDES, Laurent, VALLS, Marc

“…We present here the characterization of a new gene family, awr, found in all sequenced Ralstonia solanacearum strains and in other bacterial pathogens. We…”
Get full text

Author Correction: The effector AWR5 from the plant pathogen Ralstonia solanacearum is an inhibitor of the TOR signalling pathway by Popa, Crina, Li, Liang, Gil, Sergio, Tatjer, Laura, Hashii, Keisuke, Tabuchi, Mitsuaki, Coll, Núria S., Ariño, Joaquín, Valls, Marc

“…An amendment to this paper has been published and can be accessed via a link at the top of the paper…”
Get full text

Yeast as a Heterologous Model System to Uncover Type III Effector Function by Popa, Crina, Coll, Núria S, Valls, Marc, Sessa, Guido

“…Type III effectors (T3E) are key virulence proteins that are injected by bacterial pathogens inside the cells of their host to subvert cellular processes and…”
Get full text

Sonication contribution to identifying prosthetic joint infection with Ralstonia pickettii: a case report and review of the literature by Birlutiu, Rares Mircea, Roman, Mihai Dan, Cismasiu, Razvan Silviu, Fleaca, Sorin Radu, Popa, Crina Maria, Mihalache, Manuela, Birlutiu, Victoria

“…In the context of an increase number of primary and revision total hip and total knee arthroplasty performed yearly, an increased risk of complication is…”
Get full text

The effector AWR5 from the plant pathogen Ralstonia solanacearum is an inhibitor of the TORsignalling pathway by Popa Crina, Li, Liang, Gil, Sergio, Tatjer, Laura, Hashii Keisuke, Tabuchi Mitsuaki, Coll, Núria S, Ariño Joaquín, Valls, Marc

“…Bacterial pathogens possess complex type III effector (T3E) repertoires that are translocated inside the host cells to cause disease. However, only a minor…”
Get full text

Moral education - a MUST of the postmodern society by Popa, Crina Dumitrita

“…The character traits usually start at early ages of children and so it is good to know how this should be dealt with in order to remove deviations from the…”
Get full text

Calcium on trial: Beyond a reasonable doubt? by Fournier, Albert, Benyahia, Mohamed, Claudia, Crina Popa, Sadek, Tarek

Get full text

RipAY, a Plant Pathogen Effector Protein, Exhibits Robust γ-Glutamyl Cyclotransferase Activity When Stimulated by Eukaryotic Thioredoxins by Fujiwara, Shoko, Kawazoe, Tomoki, Ohnishi, Kouhei, Kitagawa, Takao, Popa, Crina, Valls, Marc, Genin, Stéphane, Nakamura, Kazuyuki, Kuramitsu, Yasuhiro, Tanaka, Naotaka, Tabuchi, Mitsuaki

“…The plant pathogenic bacterium Ralstonia solanacearum injects more than 70 effector proteins (virulence factors) into the host plant cells via the needle-like…”
Get full text

Ripay, a plant pathogen effector protein, exhibits robust -glutamyl cyclotransferase activity when stimulated by eukaryotic thioredoxins by Fujiwara, Shoko, Kawazoe, Tomoki, Ohnishi, Kouhei, Kitagawa, Takao, Popa, Crina, Valls, Marc, Genin, Stéphane, Nakamura, Kazuyuki, Kuramitsu, Yasuhiro, Tanaka, Naotaka, Tabuchi, Mitsuaki

“…The plant pathogenic bacterium Ralstonia solanacearum injects more than 70 effector proteins (virulence factors) into the host plant cells via the needle-like…”
Get full text

Palbociclib Rechallenge for Hormone Receptor-Positive/HER-Negative Advanced Breast Cancer: Findings from the Phase II BioPER Trial by Albanell, Joan, Pérez-García, José Manuel, Gil-Gil, Miguel, Curigliano, Giuseppe, Ruíz-Borrego, Manuel, Comerma, Laura, Gibert, Joan, Bellet, Meritxell, Bermejo, Begoña, Calvo, Lourdes, de la Haba, Juan, Espinosa, Enrique, Minisini, Alessandro Marco, Quiroga, Vanesa, Santaballa Bertran, Ana, Mina, Leonardo, Bellosillo, Beatriz, Rojo, Federico, Menéndez, Silvia, Sampayo-Cordero, Miguel, Popa, Crina, Malfettone, Andrea, Cortés, Javier, Llombart-Cussac, Antonio

“…To assess the efficacy and exploratory biomarkers of continuing palbociclib plus endocrine therapy (ET) beyond progression on prior palbociclib-based regimen…”
Get full text

3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial by Pérez-García, José Manuel, Cortés, Javier, Ruiz-Borrego, Manuel, Colleoni, Marco, Stradella, Agostina, Bermejo, Begoña, Dalenc, Florence, Escrivá-de-Romaní, Santiago, Calvo Martínez, Lourdes, Ribelles, Nuria, Marmé, Frederik, Cortés, Alfonso, Albacar, Cinta, Gebhart, Geraldine, Prat, Aleix, Kerrou, Khaldoun, Schmid, Peter, Braga, Sofia, Di Cosimo, Serena, Gion, Maria, Antonarelli, Gabriele, Popa, Crina, Szostak, Emilia, Alcalá-López, Daniel, Gener, Petra, Rodríguez-Morató, Jose, Mina, Leonardo, Sampayo-Cordero, Miguel, Llombart-Cussac, Antonio

“…PHERGain was designed to assess the feasibility, safety, and efficacy of a chemotherapy-free treatment based on a dual human epidermal growth factor receptor 2…”
Get full text

3-year invasive disease-free survival with chemotherapy de-escalation using an 18 F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial by Pérez-García, José Manuel, Cortés, Javier, Ruiz-Borrego, Manuel, Colleoni, Marco, Stradella, Agostina, Bermejo, Begoña, Dalenc, Florence, Escrivá-de-Romaní, Santiago, Calvo Martínez, Lourdes, Ribelles, Nuria, Marmé, Frederik, Cortés, Alfonso, Albacar, Cinta, Gebhart, Geraldine, Prat, Aleix, Kerrou, Khaldoun, Schmid, Peter, Braga, Sofia, Di Cosimo, Serena, Gion, Maria, Antonarelli, Gabriele, Popa, Crina, Szostak, Emilia, Alcalá-López, Daniel, Gener, Petra, Rodríguez-Morató, Jose, Mina, Leonardo, Sampayo-Cordero, Miguel, Llombart-Cussac, Antonio

“…PHERGain was designed to assess the feasibility, safety, and efficacy of a chemotherapy-free treatment based on a dual human epidermal growth factor receptor 2…”
Get full text

3-year invasive disease-free survival (iDFS) of the strategy-based, randomized phase II PHERGain trial evaluating chemotherapy (CT) de-escalation in human epidermal growth factor receptor 2-positive (HER2[+]) early breast cancer (EBC) by Cortes, Javier, Pérez-García, José Manuel, Ruiz-Borrego, Manuel, Stradella, Agostina, Bermejo, Begona, Escrivá-de-Romaní, Santiago, Calvo Martínez, Lourdes, Ribelles, Nuria, Cortés Salgado, Alfonso, Albacar, Cinta, Colleoni, Marco, Gebhart, Geraldine, Prat, Aleix, Khaldoun, Kerrou, Schmid, Peter, Di Cosimo, Serena, Popa, Crina, Alcalá-López, Daniel, Sampayo-Cordero, Miguel, Llombart-Cussac, Antonio

“…LBA506 Background: PHERGain is assessing the feasibility of a CT-free treatment based on a dual HER2 blockade with trastuzumab and pertuzumab (HP) in patients…”
Get full text

The effector AWR5 from the plant pathogen Ralstonia solanacearum is an inhibitor of the TOR signalling pathway by Popa, Crina, Li, Liang, Gil, Sergio, Tatjer, Laura, Hashii, Keisuke, Tabuchi, Mitsuaki, Coll, Núria S., Ariño, Joaquín, Valls, Marc

“…Bacterial pathogens possess complex type III effector (T3E) repertoires that are translocated inside the host cells to cause disease. However, only a minor…”
Get full text

Arabidopsis metacaspase MC1 localizes in stress granules, clears protein aggregates, and delays senescence by Ruiz-Solaní, Nerea, Salguero-Linares, Jose, Armengot, Laia, Santos, Jaime, Pallarès, Irantzu, van Midden, Katarina P, Phukkan, Ujjal J, Koyuncu, Seda, Borràs-Bisa, Júlia, Li, Liang, Popa, Crina, Eisele, Frederik, Eisele-Bürger, Anna Maria, Hill, Sandra Malgrem, Gutiérrez-Beltrán, Emilio, Nyström, Thomas, Valls, Marc, Llamas, Ernesto, Vilchez, David, Klemenčič, Marina, Ventura, Salvador, Coll, Nuria S

“…Abstract Stress granules (SGs) are highly conserved cytoplasmic condensates that assemble in response to stress and contribute to maintaining protein…”
Get full text

The awr Gene Family Encodes a Novel Class of Ralstonia solanacearum Type Ill Effectors Displaying Virulence and Avirulence Activities by Sole, Montserrat, Popa, Crina, Mith, Oriane, Sohn, Kee Hoon, Jones, Jonathan D. G., Deslandes, Laurent, Valls, Marc

“…We present here the characterization of a new gene family, awr, found in all sequenced Ralstonia solanacearum strains and in other bacterial pathogens. We…”
Get full text

The EU-funded I3LUNG Project: Integrative Science, Intelligent Data Platform for Individualized LUNG Cancer Care With Immunotherapy by Prelaj, Arsela, Ganzinelli, Monica, Trovo’, Francesco, Roisman, Laila C., Pedrocchi, Alessandra Laura Giulia, Kosta, Sokol, Restelli, Marcello, Ambrosini, Emilia, Broggini, Massimo, Pravettoni, Gabriella, Monzani, Dario, Nuara, Alessandro, Amat, Ramon, Spathas, Nikos, Willis, Michael, Pearson, Alexander, Dolezal, James, Mazzeo, Laura, Sangaletti, Sabina, Correa, Ana Maria, Aguaron, Alfonso, Watermann, Iris, Popa, Crina, Raimondi, Giulia, Triulzi, Tiziana, Steurer, Stefan, Lo Russo, Giuseppe, Linardou, Helena, Peled, Nir, Felip, Enriqueta, Reck, Martin, Garassino, Marina Chiara

“…Although immunotherapy (IO) has changed the paradigm for the treatment of patients with advanced non-small cell lung cancers (aNSCLC), only around 30% to 50%…”
Get full text